Experimental melanoma drug was rejected twice because the Food and Drug Administration questioned its study design.
Source link
About The Author
Replimune Group is expected to announce that it has reached an agreement with the FDA on a path to resubmit its experimental melanoma treatment for approval, people familiar with the matter said